|Bid||45.42 x 2100|
|Ask||45.48 x 200|
|Day's Range||45.05 - 48.62|
|52 Week Range||17.52 - 63.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.54|
CNBC's Meg Tirrell speaks with Hans Bishop, Juno Therapeutics CEO, to discuss the company's down day and progress on its cancer treatment.
Juno is now the cheapest CAR-T player, an analyst said Wednesday as he downgraded rival Bluebird on a lack of catalysts until the spring.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Juno Therapeutics, Inc. a score of 50. Our analysis is based on comparing Juno Therapeutics, Inc. with the following peers – ZIOPHARM Oncology, Inc., Incyte Corporation, Repligen Corporation and Mirati Therapeutics Inc. (ZIOP-US, INCY-US, RGEN-US and MRTX-US). Investment Outlook Juno Therapeutics, Inc. has a fundamental score of ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Juno Therapeutics, Inc. Here are 5 ETFs with the largest exposure to JUNO-US. Comparing the performance and risk of Juno Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Juno Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited ...
Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.
After reading Juno Therapeutics Inc’s (NASDAQ:JUNO) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compareRead More...
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.
Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation today released additional data from the TRANSCEND study of JCAR017 in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.
Juno Therapeutics has now gained more than 211% in value this year. Can this red-hot cancer stock keep pushing higher in 2018?
Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented new translational insights on clinical outcomes with its investigational CAR T product candidate JCAR017 at the 59th American Society of Hematology Annual Meeting and Exposition.
Short interest is moderate for JUNO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Juno Therapeutics, Inc. , a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors in combination with BCMA-directed CAR T cells.
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Juno ...